Trial record 1 of 1 for:    NCT01876446
Previous Study | Return to List | Next Study

Etirinotecan Pegol (NKTR 102) in Treating Patients With Relapsed Small Cell Lung Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by Roswell Park Cancer Institute
Sponsor:
Collaborators:
Nektar Therapeutics
Information provided by (Responsible Party):
Roswell Park Cancer Institute
ClinicalTrials.gov Identifier:
NCT01876446
First received: June 10, 2013
Last updated: August 6, 2014
Last verified: August 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)